Stock AGEN AGENUS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Agenus Inc.

Equities

AGEN

US00847G8042

Real-time Estimate Cboe BZX
Other stock markets
 12:32:50 2024-06-03 pm EDT 		5-day change 1st Jan Change
16.48 USD +5.00% Intraday chart for Agenus Inc. +8.81% +0.21%
May. 16 Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer CI
May. 07 Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
MT
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M
MT
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program
CI
Sector Update: Health Care Stocks Slipping Late Afternoon
MT
Sector Update: Health Care
MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial
MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
CI
Reverse Split: 1 of 20
FA
Agenus Stockholders Approve 1-for-20 Reverse Stock Split
MT
Earnings Flash (AGEN) AGENUS Posts Q4 Revenue $83.8M
MT
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024
CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants
MT
Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer
CI
Earnings Flash (AGEN) AGENUS Posts Q3 Revenue $24.3M
MT
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGEN Stock
  4. News Agenus Inc.
  5. Highlights